Sophomore year saw Duke celebrating its 100th year, demonstrations over the Israel-Hamas war and the effects of the Supreme ...

The East Campus library has been closed since fall 2024. The two-year project is approaching completion despite delays, with ...

Music and history shared the spotlight May 13 as community members gathered at the Lorain Public Library System Main Branch ...

LOUISVILLE, Ky. — The Louisville Free Public Library is expanding its popular telescope lending program, thanks to a grant from Genentech. The library said it is adding binocular kits at each ...

LOUISVILLE, Ky. (WDRB) — The Louisville Free Public Library will expand its telescope lending program to reach more people who want to learn about space. The program will expand to all library ...

30 Under 30 Science 2026: New Discoveries From The Cosmos To The Nanoscale 30 Under 30 Social Media 2026: Beyond The Algorithm, These Creators Are Making Millions—And Real World Impact 30 Under 30 ...

Just a few months after ripping up the central nervous system-focused portion of its RIPK1 deal with Rigel Pharmaceuticals, Eli Lilly has now thrown out the rest of the pact too. Lilly notified Rigel ...

Eli Lilly & Co.’s new weight-loss pill Foundayo has gotten off to a sluggish start, according to new prescription data, an early sign of the challenge the drugmaker will have as it tries to catch up ...

Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for Kelonia Therapeutics and its phase 1-stage myeloma therapy. Kelonia is a lentiviral ...

Pharmaceutical powerhouse Eli Lilly & Co. will buy Boston gene therapy maker Kelonia Therapeutics for at least $3.25 billion, the companies announced Monday. The acquisition will grant ...

Wall Street impressed with initial prescriptions for Lilly's Foundayo Lilly cautions early weekly figures may not be fully comprehensive Demand for Novo Nordisk's oral Wegovy also strong April 17 ...

Eli Lilly’s LLY3.07%increase; green up pointing triangle late-stage study of the efficacy and safety of a treatment for type 2 diabetes has produced positive results. Achieve-4, the longest phase 3 ...